Video

How Is Mobile Health Changing the Health Care Landscape?

Moses Zoanna, CEO of Compliance Meds Technologies, discusses the impact of mobile health.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit: Peter Hansen | stock.adobe.com
Related Content
Op-Ed: Expand Patient Choice to Lower Medication Costs
June 6th 2025

Op-Ed: Expand Patient Choice to Lower Medication Costs

Colin Edgerton, MD
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
June 6th 2025

Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Women feeling unwell and sinus on gray background - Image credit: eddows | stock.adobe.com
June 4th 2025

Study: LYR-210 Shows Promise in Chronic Rhinosinusitis with Nasal Polyps

Kennedy Ferruggia, Assistant Editor
Metabolic dysfunction-associated steatohepatitis (MASH) -- Image credit: Angelov | stock.adobe.com
June 4th 2025

GLP-1 Receptor Agonists and FGF21 Analogs May Be Key Treatments for MASH-Related Cirrhosis

Gillian McGovern, Associate Editor